D. Boral Capital Reaffirms Buy Rating for Humacyte (NASDAQ:HUMA)

D. Boral Capital reiterated their buy rating on shares of Humacyte (NASDAQ:HUMA - Free Report) in a report released on Wednesday morning,Benzinga reports. D. Boral Capital currently has a $25.00 target price on the stock.

HUMA has been the subject of several other research reports. Wall Street Zen raised shares of Humacyte from a "sell" rating to a "hold" rating in a report on Friday, June 27th. HC Wainwright started coverage on shares of Humacyte in a research report on Wednesday, May 14th. They set a "buy" rating and a $4.00 price target on the stock. Finally, Benchmark lowered their price target on shares of Humacyte from $17.00 to $14.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Humacyte currently has a consensus rating of "Moderate Buy" and an average price target of $11.71.

Humacyte Stock Down 8.0%

HUMA traded down $0.20 during trading on Wednesday, hitting $2.31. The stock had a trading volume of 4,225,577 shares, compared to its average volume of 3,840,262. The company has a market capitalization of $358.33 million, a PE ratio of -3.35 and a beta of 1.89. Humacyte has a twelve month low of $1.15 and a twelve month high of $9.79. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.28 and a current ratio of 3.68. The stock has a 50 day simple moving average of $2.24 and a two-hundred day simple moving average of $2.87.

Humacyte (NASDAQ:HUMA - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.09. The company had revenue of $0.52 million for the quarter, compared to analyst estimates of $0.46 million. On average, research analysts predict that Humacyte will post -1.27 earnings per share for the current year.

Hedge Funds Weigh In On Humacyte

Several institutional investors and hedge funds have recently bought and sold shares of HUMA. Columbia Advisory Partners LLC acquired a new position in Humacyte in the 1st quarter valued at about $27,000. Hamilton Lane Advisors LLC acquired a new position in Humacyte in the 1st quarter valued at about $37,000. Letko Brosseau & Associates Inc. acquired a new position in shares of Humacyte in the 1st quarter worth approximately $42,000. Pallas Capital Advisors LLC acquired a new position in shares of Humacyte in the 2nd quarter worth approximately $42,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new position in shares of Humacyte in the 2nd quarter worth approximately $49,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.